Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.74 |
| ▸ | GAA | P10253 | 5/20 | 0.57 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | GLA | P06280 | 2/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | CASP7 | P55210 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | DRD1 | P21728 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL858261 | 0.93 | KDM4E (0.74) | KDM4EGAAPOLBALDH1A1HSD17B10 | |
| SCHEMBL169553 | 0.86 | GAA (0.66) | KDM4EGAAPOLBALDH1A1HSD17B10 | |
| SCHEMBL30447954 | 0.85 | KDM4E (0.56) | KDM4EGAAPOLBALDH1A1HSD17B10 | |
| SCHEMBL31408659 | 0.85 | KDM4E (1.00) | KDM4EGAAPOLBALDH1A1HSD17B10 | |
| SCHEMBL372600 | 0.85 | KDM4E (1.00) | KDM4EGAAPOLBALDH1A1HSD17B10 | |
| SCHEMBL25341632 | 0.85 | KDM4E (0.56) | KDM4EGAAPOLBALDH1A1HSD17B10 | |
| Hydrochloric Acid SCHEMBL7410965 | 0.85 | GAA (0.64) | KDM4EGAAPOLBALDH1A1HSD17B10 | |
| SCHEMBL17653164 | 0.84 | KDM4E (0.51) | KDM4EGAAPOLBALDH1A1HPGD | |
| SCHEMBL29915081 | 0.84 | KDM4E (0.51) | KDM4EGAAPOLBALDH1A1MAPT | |
| SCHEMBL15217022 | 0.84 | KDM4E (0.51) | KDM4EGAAPOLBALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022135-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | 1CBIO INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-12325720-B2 | Ectonucleotide pyrophosphatase-phosphodiesterase-1 (ENPP1) inhibitors and uses thereof | 1CBIO, INC. (US) | 2025-06-10 | — | — | US | disclosed |
| EP-4524139-A1 | IMIDAZOPYRIDAZINE SUBSTITUTED BENZENE RING DERIVATIVE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2025-03-19 | — | — | EP | disclosed |
| US-20240352046-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | 1CBIO INC (US) | 2024-10-24 | — | — | US | disclosed |
| WO-2024178390-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2024-08-29 | — | — | WO | disclosed |
| US-20240109891-A1 | NOVEL SUBSTITUTED TRICYCLIC AZA-HETEROCYCLES AS SOS1 INHIBITORS | VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2024-04-04 | — | — | US | disclosed |
| CN-117561258-A | Novel substituted tricyclic aza heterocycles as SOS1 inhibitors | 唯久生物技术(苏州)有限公司 | 2024-02-13 | — | — | CN | disclosed |
| CN-117069725-A | Imidazopyridazine substituted benzene ring derivative, preparation method, pharmaceutical composition and application | 上海赛默罗生物科技有限公司 | 2023-11-17 | — | — | CN | disclosed |
| WO-2023216753-A1 | IMIDAZOPYRIDAZINE SUBSTITUTED BENZENE RING DERIVATIVE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE | 上海赛默罗生物科技有限公司 | 2023-11-16 | — | — | WO | disclosed |
| EP-4236928-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | 1Cbio, Inc. (US) | 2023-09-06 | — | — | EP | disclosed |
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | AIKAWA MINA | 2010-08-26 | — | — | US | disclosed |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | JAIN RAMA | 2010-05-13 | — | — | US | disclosed |
| CN-101652352-A | Quinazolines for PDK1 inhibition | NOVARTIS VACCINES & DIAGNOSTIC | 2010-02-17 | — | — | CN | disclosed |
| WO-2009153313-A1 | 2 -ARYLAMINOQUINAZOLINES FOR TREATING PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2009-12-23 | — | — | WO | disclosed |
| EP-2125755-A2 | QUINAZOLINES FOR PDK1 INHIBITION | Novartis Ag (CH) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008079988-A2 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS AG (CH) | 2008-07-03 | — | — | WO | disclosed |
| EP-0686625-B1 | ANTHRANILIC ACID DERIVATIVE | EISAI CO LTD (JP) | 1999-05-26 | — | — | EP | disclosed |
| US-5716993-A | PHOSPHODIESTERASE ENZYME INHIBITOR FOR TREATING CARDIOVASCULAR DISORDER, ANGINA PECTORIS, HYPERTENSION, ASTHMA | EISAI CO., LTD. (JP) | 1998-02-10 | — | — | US | disclosed |
| CN-1118595-A | Anthranilic acid derivative | EISAI CO LTD (JP) | 1996-03-13 | — | — | CN | disclosed |
| EP-0686625-A1 | ANTHRANILIC ACID DERIVATIVE | Eisai Co., Ltd. (JP) | 1995-12-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | KDM4E 915/4885GAA 1908/4885POLB 1689/4885 |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | PDK1, PDK2, PDK3 | KDM4E 1195/4885GAA 1566/4885POLB 989/4885 |
| US-20260022135-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, NCEH1 | KDM4E 4523/4885GAA 1454/4885POLB 904/4885 |
| US-20240109891-A1 | NOVEL SUBSTITUTED TRICYCLIC AZA-HETEROCYCLES AS SOS1 INHIBITORS | SOS1, SOS2, KSR1 | KDM4E 2082/4885GAA 2772/4885POLB 3641/4885 |
| US-20240352046-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, ENPP2 | KDM4E 3129/4885GAA 189/4885POLB 934/4885 |
| US-12325720-B2 | Ectonucleotide pyrophosphatase-phosphodiesterase-1 (ENPP1) inhibitors and uses thereof | ENPP1, ENPP3, ENPP2 | KDM4E 3129/4885GAA 189/4885POLB 934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.